4basebio Plc - Final Results and Notice of AGM
Outlook
During 2025 and at the start of 2026, 4basebio has made substantial progress,positioningthe Company to capitalise on exciting opportunities ahead as next-generation genetic medicines market continuesitsrapid expansion.This is shown throughsignificant progress both in revenue and the development of its customer pipeline.
4basebio PLC
("4basebio" or the "Company")
Final Results and Notice of AGM
– 20 May
FINANCIAL HIGHLIGHTS
OPERATIONAL HIGHLIGHTS
POST-PERIOD END HIGHLIGHTS
Dr, Chief Executive Officer of 4basebio, commented:
“2025 represented a step-change for the Company, with GMP accreditation, a growing customer base and commercial appointments underpinning our transition into a highly commercially focused business. 4basebio’s expertise in enzymatic DNA manufacturing offers superior safety and efficacy compared with plasmid DNA, and we are seeing more advanced therapy developers recognising these advantages, underlined by the continued clinical use of our technology.
“Since taking the role of CEO of 4basebio, I’ve been focused on putting the right team in place for this commercial phase and I’m excited by the progress we have achieved. We now have the personnel and infrastructure to drive delivery. After the period end, we’ve seen this reflected in strong commercial progress, enabled by a more diverse product offering and exceptional scientific and commercial teams. We believe 4basebio is extremely well positioned to benefit from the substantial and growing demand for synthetic DNA and accordingly we expect to see significant growth in revenues 2026 and beyond.”
Dr , Executive Chair of 4basebio, added:
“4basebio is at a pivotal point in its development. We have a fantastic team in place, strengthening the Company’s ability to take advantage of the growing demand in genetic medicine markets for enzymatic manufacturing solutions.
“I want to thank our Board and share holders for their continued support. We are excited about the opportunities ahead and look forward to continuing to leverage our innovative offering, technical expertise and commercial infrastructure to drive further market penetration.”
This announcement contains inside information for the purposes of Article 7 of the version of the Market Abuse Regulation (EU) No. 596/2014 (“UK MAR”), as amended and forming part of law by virtue of the European Union (Withdrawal) Act 2018. Upon publication of this announcement, this inside information is now considered to be in the public domain.
Investor Presentation
The Company will host a presentation for institutional investors today at at the offices of RBC Capital Markets,
Annual Reports and Accounts and Notice of Annual General Meeting
The Annual Report and Accounts for the year ended , together with Notice of the Company’s Annual General Meeting, which is to be held on at at the offices of 4basebio plc, are expected to be uploaded to the Company’s website and posted to shareholders shortly.
The Annual General Meeting will be followed by a presentation from the Company through the Investor Meet Company platform. Further information will be provided in due course.
For further enquiries, please contact:
About 4basebio
4basebio (AIM: 4BB) is a -based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality. For more information, visit
Joint statement from the Chief Executive Officer and Executive Chair
We are pleased to report on the year ended , which represented a pivotal year for 4basebio as we continued our transformation from a research-focused organisation into a commercially driven enterprise aiming to deliver synthetic, cell-free DNA as the foundation for every genetic medicine. While the advanced therapeutics sector faced challenging market conditions that impacted timelines and funding across the industry, we delivered significant operational progress that has positioned us strongly for accelerated growth.
During 2025, we continued to enhance and further innovate our product offering to address the growing demand of innovators working across multiple modalities including viral vectors, gene editing, mRNA medicines, DNA and mRNA for vaccines. These advancements diversified our customer base to more than 125 partners. The broad customer base now spans emerging and established biotechs and large pharmaceutical organisations. To date, we have supported four Investigational New Drug (IND) applications and Clinical Trial Authorisations (CTAs) underscoring our role as a trusted partner in advancing therapeutic development.
Regulatory Milestone Achievement
In , we achieved a critical regulatory milestone by securing MIA IMP Good Manufacturing Practice (GMP) certification from the Medicines and Healthcare products Regulatory Agency (MHRA). This certification authorises us to supply GMP-grade synthetic DNA for clinical programmes in advanced therapies and genetic medicines, cementing our capability to support partners throughout their entire clinical development lifecycle with premium, clinical-grade materials.
Continued Clinical Validation
The clinical and commercial validation of our platform reached a significant milestone in October when a global Tier 1 pharmaceutical partner initiated patient dosing with an mRNA product utilising our proprietary opDNA® template in a Phase I/II clinical trial. This achievement, stemming from a supply agreement established in , demonstrates the real-world impact and reliability of our technology.
Strengthening Leadership for Scale
In , we appointed as Executive Chairman, a strategic addition that brings over 25 years of experience building multi-national CDMOs focused on biologics and advanced therapies. Manja's deep industry expertise and proven track record in scaling operations will be instrumental as we meet the escalating demand for our pDNA-free synthetic DNA platform.
In the second half of the year, we established a new global commercial leadership team under , a 25-year life sciences veteran with exceptional experience building go-to-market operations for manufacturing services for advanced therapies or genetic medicines. Christine was promoted to Chief Commercial Officer in , and has accelerated our North American and European expansion in Business Development and Marketing activities leading to significant pipeline growth.
Accelerating Commercial Momentum
Despite market headwinds, particularly from the US administration with regulatory concerns from FDA leadership and widespread cuts to the National Institute of Health’s budget, the Company delivered a 100% growth in DNA sales revenue. The impact of our strategic investments and new leadership additions became evident in the second half of 2025. Our new business pipeline value increased by 41% from Q3 to Q4 2025, reflecting strong market demand and the effectiveness of our enhanced commercial capabilities. This robust pipeline of pre-clinical and clinical opportunities, which has continued to expand post-period end, positions 4basebio for rapid commercial and financial growth in the years ahead.
New Chief Executive Officer and Chief Financial Officer
Post-period end in , Dr was appointed as Chief Executive Officer, after more than five years with the business, most recently as Chief Operating Officer. Amy played a key role in developing the IP surrounding the DNA platform and its application across the cell and gene therapy space, alongside scaling 4basebio’s GMP manufacturing capabilities, strengthening direct engagement with top-tier biopharma customers and supporting the Company’s growth operationally and strategically. Amy will lead the Company’s accelerated commercial growth strategy. Amy succeeded Dr Heikki Lanckriet, Founder of the Company, who has remained on the Board as a Non-Executive Director.
Following Amy’s transition to the role as CEO, 4basebio announced the appointment of as Chief Operating Officer. Scott brings more than 30 years’ experience in bioprocess development and scale up and clinical and commercial manufacturing of biologics and cell and gene therapies and will be responsible for scaling the Company’s innovative synthetic DNA platform as our commercial traction continues to accelerate.
was appointed CFO and will join the business in . Richard is an accomplished leader with over 30 years’ senior finance and strategic experience within the pharmaceutical and biotechnology sector, leading both public and private companies from research through all clinical phases, regulatory approval and commercialisation.
Financial performance
Overcoming some of the commercial headwinds arising in 2025 and with the commercial team demonstrating significant pipeline acceleration, the Group expects continued strong revenue growth in 2026. The Group expects to remain loss-making in 2026 and will draw on its cash resources to fund those losses.
Driving growth is the primary focus of the business. While the broader biotech fundraising environment and evolving US regulatory policies continue to present variable timelines for projects, the strong growth in commercial opportunities and pipeline demonstrates the rapidly growing demand for synthetic DNA whilst commercial visibility steadily improves. As a result, we anticipate continued acceleration in our pipeline and revenue though 2026 as clients continue to adopt cell-free DNA in their assets.
To support this commercial trajectory, 2026 will be a year of significant operational and product development. The Company’s confidence in its commercial success is underscored by the decision to relocate to a new innovation hub and manufacturing facility in , planned for late summer 2026, which will significantly expand our production footprint and increasing customer throughput.
Our vision is to become a worldclass manufacturer focused on delivering synthetic, cell-free DNA as the foundation for every genetic based medicine.
While we anticipate continued strategic investments in our technologies and commercial infrastructure, the Board remains highly confident that these foundational steps will yield substantial, long-term shareholder and stakeholder value. We expect that our current cash levels will provide the Group with funding into late-2027.
We would like to take this opportunity to thank our shareholders for their continued support and our dedicated team for their exceptional work in delivering this transformational year. We look forward to much progress in the years ahead.
Dr Dr
Executive Chair Chief Executive Officer
Consolidated statement of profit or loss and other comprehensive income
For the year ended
All of the loss for the year is from continuing operations.
Consolidated statement of financial position
As at
Consolidated statement of changes in equity
For the years ended and
Consolidated statement of cash flows
For the year ended
Notes to the financial statements
1. General
4basebio PLC (the “Company” or “4basebio”) is registered in and with company number 13519889. The Company is domiciled in and the registered office of the Company is , Over, CB24 5QE. 4basebio PLC is the parent of a group of companies (together, “the Group”). The Group focuses on life sciences, in particular the development of synthetic DNA and nanoparticles suitable for inclusion in, or delivery of, therapeutic payloads for gene therapies and gene vaccines.
The Company trades on London Stock Exchange’s AIM market. The international securities number (ISIN) for its AIM-traded shares is GB00BMCLYF79; its ticker symbol is 4BB.L.
The consolidated financial statements of 4basebio PLC and its subsidiaries for the year ended were authorised for issue in accordance with a resolution of the Directors on .
2. Basis of preparation
The consolidated financial statements of 4basebio PLC (“the Group”) for the financial year ended have been prepared in accordance with -adopted International Accounting Standards in conformity with the requirements of the Companies Act 2006.
The consolidated financial statements comprise the results of 4basebio PLC, 4basebio S.L.U., 4basebio UK Limited, 4basebio Discovery Limited and 4basebio Inc. (incorporated ) for the whole year (or, in the case of 4basebio Inc., from the date of incorporation).
The above summary has been extracted from the report and financial statements and, accordingly, references to notes and page numbers may be incorrect. Shareholders are advised to read the full version of the report and financial statements which will be available from the Company’s website shortly.
3. Earnings per share
The calculation of the basic and diluted loss per share for continuing operations was based on the weighted average number of shares as determined above. The numerator is the loss after tax from continuing operations. Outstanding share options have not been included in the calculation of the diluted loss per share because they would be anti-dilutive since the business is loss making.
4. Approval of the financial statements
The financial statements were approved by the Board of Directors and authorised for issue on .
-- Revenue for the period of £1.7 million (FY 2024: £0.9 million),
representing growth of 81%, with revenue from clinical stage projects
contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue
increasing by 100%
-- Loss for the period of £16.9 million (FY 2024: £12.3 million),
reflecting continued planned investment in commercial infrastructure,
GMP capabilities and product development
-- Cash and cash equivalents of £17.8 million at
(FY 2024: £34.6 million), with a subsequent €7 million drawdown under
the Deutsche Balaton facility in providing the Group with
funding into late-202731 December 2025 April 2026 -- Growing commercial momentum with a diverse and broadened customer
base, driven by an expanding product offering focusing on gene editing,
mRNA, viral vectors and DNA vaccines
-- New business pipeline value increased by 41% from Q3 to Q4 2025,
reflecting strong market demand and enhanced business development focus;
approximately half of the pipeline is GMP/HQ opportunities, with
momentum in new business continuing post-year end
-- Receipt of MIA IMP Good Manufacturing Practice (GMP)
certification from the UK’s Medicines and Healthcare Products Regulatory
Agency (MHRA), significantly enhancing the Company’s ability to support
customers through the clinical development lifecycle
o Tier 1 pharmaceutical partnership commenced, with supply of
enzymatically-produced DNA for mRNA vaccine Phase I/II programme
-- Customer base growth to 125+ customers, with four
Investigational New Drug (IND) and Clinical Trial Authorisations (CTAs)
supported
-- Further clinical validation achieved through supply of opDNA™
for an mRNA vaccine trial
-- Appointment of senior, US and EU-focused commercial team
experienced in genetic medicines and CDMO services, accelerating
4basebio’s business development activity in
-- Expansion of intellectual property portfolio to 33 patent
families, reinforcing 4basebio’s market leading position in synthetic
DNANorth America -- Dr appointed as Executive Chair, bringing 25 years
of experience in biologics and advanced therapies, including executive
roles at Catalent’s cell, gene, and protein thearpy division, DSM
Biologics, and Patheon BiologicsManja Boerman -- Senior leadership team appointed to align 4basebio for
acceleration of commercialisation, with the appointment of Dr
as Chief Executive Officer in
-- named Chief Financial Officer with a start date
of
-- promoted to Chief Commercial Officer to lead
global Business Development
-- Appointment of , a 30-year veteran of bioprocess
development and commercial manufacturing as Chief Operating Officer, to
lead the building of 4basebio’s commercial infrastructure -
-- Signed a new multi-year, approximately seven-figure Clinical
Supply Agreement reflecting increased commercial momentum, as 4basebio’s
opDNA® technology will support a Phase II clinical trial of
immunotherapy candidateAmy Walker Richard Bungay Christine Wolosin Scott Lorimer February 2026 July 2026 4basebio PLC +44 (0)12 2396 7943
Dr , CEO
Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
/ /
Cavendish Capital Markets Limited (Joint Broker) +44 (0)20 7220 0500
/
RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
/
ICR Healthcare (Media and Investor Relations) +44 (0)203 707 5700
/Amy Walker Jo Turner Sandy Jamieson Ed Downes Geoff Nash Nigel Birks Kathryn Deegan Matthew Coakes Mary-Jane Elliott Jessica Hodgson [in £'000] 2025 2024
Revenues 1,693 933
Cost of goods sold (719) (303)
Gross profit 974 630
Administrative expenses (17,701) (13,866)
Other operating expenses (969) (114)
Other operating income 96 1,308
Operating result (17,600) (12,042)
Finance income 884 140
Finance costs (887) (752)
Loss before tax (17,603) (12,654)
Income tax credit 698 321
Loss for the year (16,905) (12,333)
Loss per share - basic and diluted (in £/share) (1.09) (0.94)
Items that may be reclassified subsequently to
profit or loss:
Foreign exchange differences on translation of 316 (313)
foreign operations
Total comprehensive loss for the year (16,589) (12,646)[in £'000] 2025 2024
Assets
Other intangible assets 4,825 3,480
Property, plant and equipment 4,027 4,326
Other non-current assets 33 33
Total non-current assets 8,885 7,839
Current assets
Inventory 657 374
Trade receivables 289 283
Other current assets 1,915 1,627
Cash and cash equivalents 17,803 34,604
Total current assets 20,664 36,888
Total assets 29,549 44,727
Liabilities
Trade payables (1,052) (1,694)
Lease liabilities (130) (41)
Other current liabilities (1,607) (1,383)
Other financial liabilities (39) (147)
Total current liabilities (2,828) (3,265)
Non-current liabilities
Financial liabilities (15,645) (14,294)
Lease liabilities (691) (734)
Other liabilities (274) (54)
Total non-current liabilities (16,610) (15,082)
Total liabilities (19,438) (18,347)
Net assets 10,111 26,380
Equity
Share capital 13,799 13,772
Share premium 37,254 37,250
Capital reserves 14,151 13,864
Foreign exchange reserve (155) (471)
Merger reserve 688 688
Accumulated losses (55,626) (38,723)
Total equity 10,111 26,380[in FX P&L
£'000] Share Share Capital reserve Merger reserve Total
capital premium reserve reserve equity
At 1 13,864 (471) 688 26,380
January 2025 13,772 37,250 (38,723)
Loss for - - - - -
the year (16,905) (16,905)
FX
translation - - - 316 - - 316
differences
Shares
issued in 27 4 - - - - 31
period
(SIP/options)
Share-based - - 288 - - - 288
payment
charge
At 31 688
December 2025 13,799 37,254 14,151 (155) (55,628) 10,111
At 1 706 13,530 (158) 688 (492)
January 2024 11,132 (26,390)
Loss for - - - - -
the year (12,333) (12,333)
FX
translation - - - (313) - - (313)
differences
Shares
issued in 2,640 36,544 - - - - 39,184
period
Share-based - - 334 - - - 334
payment
charge
At 31 688
December 2024 13,772 37,250 13,864 (471) (38,723) 26,380[in £'000] 2025 2024
Cash flows from operating activities
Loss for the year (16,905) (12,333)
Adjustments for:
Tax charge (698) (321)
Tax received 412 117
Depreciation of property, plant and equipment 940 800
Amortisation of capitalised development costs 205 133
and patents
Share-based payment charge 288 334
Foreign exchange adjustments 768 (608)
Other operational foreign exchange and non-cash 411 (101)
items
Net finance (income)/costs 3 612
Changes in working capital:
(Increase)/decrease in inventories (283) (49)
(Increase)/decrease in trade receivables and (294) (76)
other current assets
Increase/(decrease) in trade payables and other (437) 748
current liabilities
Net cash flow from operating activities (15,588) (10,744)
Cash flows from investing activities
Investments in property, plant and equipment (458) (697)
Investments in capitalised development and (1,181) (874)
intangible assets
Interest received 909 72
Net cash flow from investing activities (730) (1,499)
Cash flows from financing activities
Proceeds from issue of equity (net of expenses) - 38,484
Proceeds from exercise of share options 31 700
Drawdowns under loan facility - 8,800
Repayments under loan facility (274) (3,988)
Lease liability repayments (IFRS 16) (126) (115)
Interest paid (72) (86)
Net cash flow from financing activities (441) 43,795
Net (decrease)/increase in cash and cash (16,759) 31,552
equivalents
Foreign exchange differences (42) (17)
Cash and cash equivalents at 1 January 34,604 3,069
Cash and cash equivalents at 31 December 17,803 34,6042025 2024 Numerator [in £'000] Loss for the period (16,905) (12,333) Denominator [number of shares] Weighted average number of registered shares 15,507,339 13,116,570 Basic and diluted loss per share (£) (1.09) (0.94)

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE